Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 2 Colorectal Neoplasms 2 Vulvar Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Prostatic Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Melanoma 1 Locally Advanced Rectal Carcinoma 1 Hypoxia 1 Gliosarcoma 1 Glioma 1 Genetic Diseases, Inborn 1 Esophageal Neoplasms 1 Circulating Tumor DNA 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Astrocytoma 1

Interventions

Docetaxel 171 Radiotherapy 144 Magnetic Resonance Spectroscopy 142 Leuprolide 112 Prednisone 108 enzalutamide 102 Radiosurgery 101 Abiraterone Acetate 94 Androgen Antagonists 91 Goserelin 83 bicalutamide 81 gallium 68 PSMA-11 70 Surveys and Questionnaires 63 apalutamide 57 Specimen Handling 56 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55 Radiation 47 Gonadotropin-Releasing Hormone 45 Standard of Care 44 Biopsy 44 Brachytherapy 42 Radiotherapy, Intensity-Modulated 40 Blood Specimen Collection 40 darolutamide 39 abiraterone 39 cabazitaxel 35 Exercise 35 Carboplatin 33 Pluvicto 32 Triptorelin Pamoate 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Prostatic Neoplasms × Circulating Tumor DNA × Clear all

NCT05702619 2023-01-27

HYPROGEN

The Christie NHS Foundation Trust

Hypoxia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡